Страна: Канада
Език: английски
Източник: Health Canada
METHYLPREDNISOLONE (METHYLPREDNISOLONE SODIUM SUCCINATE)
PFIZER CANADA ULC
H02AB04
METHYLPREDNISOLONE
40MG
KIT
METHYLPREDNISOLONE (METHYLPREDNISOLONE SODIUM SUCCINATE) 40MG
INTRAMUSCULAR
10X1ML
Prescription
ADRENALS
Active ingredient group (AIG) number: 0106290002; AHFS:
MARKETED
2012-01-11
_SOLU-MEDROL (methylprednisolone sodium succinate) Product Monograph _ _Page 1 of 40_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr SOLU-MEDROL ® Methylprednisolone Sodium Succinate for Injection USP Sterile Powder, 500 mg, 1 g Vials, intravenous and intramuscular Pr SOLU-MEDROL ® ACT-O-VIALS ® Methylprednisolone Sodium Succinate for Injection USP Sterile Powder and Diluent, 40 mg, 125 mg, 500 mg, 1 g ACT-O-VIALS, intravenous and intramuscular Glucocorticoid Pfizer Canada ULC 17,300 Trans-Canada Highway Kirkland, Quebec H9J 2M5 Date of Initial Authorization: March 20, 1991 Date of Revision: MAR 14, 2024 Submission Control Number: 280527 ® TM Pfizer Enterprises SARL Pfizer Canada ULC, Licensee ® TM Pharmacia & Upjohn Company LLC Pfizer Canada ULC, Licensee © Pfizer Canada ULC 2024 _ _ _SOLU-MEDROL (methylprednisolone sodium succinate) Product Monograph _ _Page 2 of 40_ RECENT MAJOR LABEL CHANGES 7 WARNINGS AND PRECAUTIONS 01/2023 8 ADVERSE REACTIONS 03/2024 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED . RECENT MAJOR LABEL CHANGES ............................................................................................ 2 TABLE OF CONTENTS .............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ...................................................................... 4 1 INDICATIONS ............................................................................................................... 4 1.1 Pediatrics ................................................................................................................ 5 1.2 Geriatrics ................................................................................................................ 5 2 CONTRAINDICATIONS ................................................................................................. 5 4 DOSAGE AND ADMINISTRATION ......................................... Прочетете целия документ